A private investment firm is actively investing in early-stage life science companies, primarily from Series A to beyond. Typical investment size ranges between $5-20M USD, and the firm works together with its network of other active investment firms and family offices to form investment syndicates. The firm is focused on companies based in USA and Canada, but is open to evaluating highly promising companies beyond North America.
The firm invests in therapeutics and devices, and digital health to a much lesser extent. The firm will not consider wearables. With regards to therapeutics, the firm is most interested in clinical stage companies (pre-clinical will most likely be considered too early stage) in the anti-infective space. The firm does look at other modalities and indications given that they are fairly advanced clinical assets. In terms of medical devices, the firm will consider those that are very close to, or already gained FDA approval. The firm is agnostic in terms of subsectors and indications, but is most interested in technologies that address a large market and can be applied in a wide scale. The firm has reviewed technologies in ophthalmology, cardiovascular, and pulmonary indications with positive interest.
The firm has no specific company or management team requirements, though strong intellectual property is considered a huge plus. The firm generally acts as a co-investor, but also engages fellow investors in their network to syndicate investment rounds.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: Private Investment Firm Invests Up to $20M in USA and Canada-Based Companies, Most Interested in Therapeutics & Medical Device Sectors
17 MarHot Investor Mandate: PE Firm Invests Up to $10M in Early to Growth-Stage Therapeutics, Devices, Diagnostics, and Digital Health Companies With India Angle
17 MarAn India-focused private equity firm makes early-growth investments in several sectors including the life sciences. The firm seeks to invest in Series A or B and generally invest USD 1-10 million per company. The firmĀ focuses on India-based companies, but it also invests in companies based outside of India as long as they have some presence in India.
In the life sciences, the firm is interested in therapeutics, specialty pharma, medical devices, diagnostics, healthcare IT, and services. The firm prefers products that require relatively shorter clinical trials. For therapeutics, the firm generally invests in products in pre-clinical stage and is indication agnostic, but typically does not consider orphan indications. For medical devices, the firm will consider all classes and generally looks for devices beyond proof-of-concept.
The firm can both lead or act as co-investor in syndicate.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Hot Investor Mandate: Investment Firm With Ties to Large Health System Invests Up to $20M in Global Medical Device, Diagnostics, Digital Health and Healthcare Services Companies
17 MarAn investment firm based in USA that manages funds of a large health system looks to invest in companies of strategic interest to its health system investors while seeking strong financial returns. With the fund, the firm is looking to make investments ranging from $1 – $20 million over the lifetime of the investment in stages ranging anywhere from seed to buyout. The firm is actively reviewing new opportunities and will consider companies located around the globe. The firm also manages other funds that seek to invest in food and agriculture companies and insurtech companies, respectively.
Within the healthcare space, the firm looks to invest in sectors of Healthcare IT, Services, Diagnostics, and Devices.
The firm is looking for companies with experienced management teams and prefers working with complete teams although they also have experience and are willing to work with incomplete management teams as well. The firm is looking for privately held companies and is open to either lead or co-invest in rounds. The firm generally looks to take a board seat following an investment.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Whoās Pitching at Digital RESI March?
10 MarByĀ Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN
The Innovatorās Pitch Challenge (IPC) returns in two weeks as part of Digital RESI, March 22-24. The IPC is a highly anticipated and popular feature of the virtual Digital RESI format. Representing therapeutics, medical devices, diagnostics, and digital health, finalists use the opportunity to showcase their technology to registered RESI attendees, which include over 300 active early-stage life science investors. Each company will have a dedicated landing page that includes their pitch video, slide deck, executive summary, and other marketing collateral. These companies will also be engaging in a live Q&A session with investors who have relevant expertise, which will help them prepare for future investor meetings. These sessions often lead to engaging follow-on discussions and valuable, long-term connections.
Check out each finalist below and learn more about the Digital RESI JPM winners!
- First Place: Amplified Sciences ā Making a Difference One Impression at a Time
- Second Place: OncoXome ā Family Matters in Fundraising
- Third Place: Prolifagen ā Ascending the Steep Slope of Preclinical Fundraising
Digital RESI March 2022 IPC Finalists
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Workshops at Digital RESI March
10 MarByĀ Alexander Vassallo, Manager of Business Development West Coast (US), LSN
Digital RESI March provides valuable opportunities to partner with hundreds of active investors seeking early-stage assets in life science and healthcare, but equally valuable are the resources provided by key strategic partners providing the services necessary for business growth. Life Science Nation (LSN) is pleased to feature experienced industry professionals attending the March 22-24 Digital RESI partnering conference and hosting exciting workshops designed specifically to address the pain points of early-stage scientist-entrepreneurs raising their Seed to Series B funding rounds. Check out our workshops below and register to start booking meetings today!
Tuesday, March 22, 12 PM EDT
Keeping Your Life Science Startup Out of the āValley of Deathā
Instructor: Nishta Rao, MBA, Managing Director, Life Sciences, First Republic Bank
Moderated by First Republic Bankās Nishta Rao, hear from CEOs and founders on their pain points and strategies on navigating their company out of the valley of death.
Tuesday, March 22, 1 PM EDT
Employee Risk Mitigation in Startups
Instructors:
Samuel Bilsky, Sales Consultant, TriNet
Anna Evans, Senior Consultant ā Technology, TriNet
In the digital age, itās important for entrepreneurs to prioritize their companyās most valuable asset: people. This session will detail how full-service HR can save precious time for entrepreneurs to focus on what matters while knowing their team is taken care of. In a sea of possibilities, understand your HR options, learn about PEO services, and how they can help scale your business with big-company benefits and infrastructure. Thereās no one-size-fits all, so get tips on finding the right HR solution for your organization.
Wednesday, March 23, 12 PM EDT
Branding & Messaging: Seed to Series B
Instructors:
Claire (Chae-Kyeong) Jeong, VP of Investor Research, Asia Business Development, Life Science Nation
Candice He, VP of Business Development, Global Investment Strategist, Life Science Nation
To win capital, you must stand out from the crowd. The first way to do that is to have top-notch marketing collateral. This bootcamp discusses how to provide potential investors with high-quality, professional materialsāmaterials that engage them, communicate your message clearly and concisely, and present the information they want to see in a way that helps them to decide quickly and easily if you are a potential fit for their needs.
Thursday, March 24, 12 PM EDT
Negotiating Term Sheets: Whatās Best for the Company and Whatās Best for You?
Instructors:
Mark Mihanovic, Partner, McDermott Will & Emery
Aroma Sharma, Partner, McDermott Will & Emery
This interactive workshop, organized and led by McDermott Will & Emery, will provide wisdom to early-stage CEOs and management on the latest trends in term sheets, with a focus on founder and management equity opportunities. The workshop will cover common issues of concern to entrepreneurs (valuation/dilution, liquidation preference, board makeup, protective provisions, anti-dilution). Experts from the legal, investment and entrepreneurial community will discuss the interplay of financing milestones in the term sheet discussion.
Fill Your Dance Card in March
10 MarByĀ Joey Wong, Investor Research Analyst, Hong Kong BD, LSN
As Digital RESI, March 22-24 ramps up, so has interest from the RESI investor community. With over 300 investors already registered for the event, including large pharma/medtech, traditional VCs, family offices/private wealth, and angel groups, this virtual event is shaping up to be buzzing with activity and digital meetings.
What sets RESI apart from many partnering events is the Life Science Nation (LSN) dedicated Investor Research Team responsible for ensuring that each investorās partnering profiles are comprehensive and up-to-date. This conference is an excellent opportunity for entrepreneurs and founders to expand their network in the industry and connect with investors and strategic partners that are a fit for their company. With less than two weeks left, the partnering activities are at their peak and there is no better time to reach out to investors and book meetings. Register now to connect with these investors at Digital RESI March:
Hot Investor Mandate: Healthcare-Focused VC with USA and Asia Offices Invests in Cutting Edge Life Sciences and Digital Health Solutions Across the Globe
10 MarAn early-stage healthcare venture fund with teams in USA and Asia looks to invest in visionary teams and cutting-edge technologies in both life science and digital health solutions.
The firm’s philosophy is not to take a one-size-fits-all approach to investing. The firm draws from their domain expertise and diversified experiences across the full healthcare spectrum to cover both Biopharma and Digital Health sectors. The firm’s aim is to support companies that can achieve differentiated therapeutic results through truly novel approaches. Combining scientific rigor and strategic connections within our network, the firm provides guidance and add value to our portfolio companies as they grow. The firm is seeking to work with companies from late Seed to Series B, and is open to global opportunities.
The firm is focused on two main investment themes: (1) Life Sciences – the firm looks for sound scientific principles and seek innovative approaches, including breakthrough medicines and platform technologies. The firm’s key areas of interest include neurological diseases, metabolic diseases, and infectious diseases. The firm’s investment team engages with entrepreneurs and companies from early pre-clinical development where there is compelling science with cell and/or animal model proof of concept data and invests through pre-clinical and early clinical proof of concept stages; (2) Digital Health / Bio IT
Digital health is a transformational area in healthcare. The firm looks for technology platforms that enable pertinent scientific insights into drug development and design or enhanced delivery of care from providers to patients. Key areas of interest include synthetic biology, machine learning for drug discovery (proteomics and metabolomics), and tools that help reduce healthcare costs.
The firm is looking for experienced management teams with strong scientific expertise and management skills.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Subscribe
Life Science Nation
RESI Conference Series
Investor Platform Demo
Company Platform Demo
Next Phase Newsletter 